Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer

Trial Profile

Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2017.
    • 09 May 2016 Efficacy results will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, according to an Oncothyreon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top